Provisional peer-reviewed toxicity values for perfluorobutane sulfonic acid (CASRN 375-73-5) and related compound potassium perfluorobutane sulfonate (CASRN 29420-49-3)

Provisional peer-reviewed toxicity values for perfluorobutane sulfonic acid (CASRN 375-73-5) and related compound potassium perfluorobutane sulfonate (CASRN 29420-49-3)

This assessment is a toxicity assessment developed by the U.S. EPA's Office of Research and Development (ORD) Center for Public Health and Environmental Assessment (CPHEA). A provisional peer-reviewed toxicity value (PPRTV) is defined as a toxicity value derived for use in the Superfund Program...

Descripción completa

Detalles Bibliográficos
Otros Autores: Lambert, Jason C., author (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Cincinnati, OH : Center for Public Health and Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency 2021.
Materias:
Toxicity testing.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820266106719
Tabla de Contenidos:
  • AUTHORS, CONTRIBUTORS, AND REVIEWERS
  • PREFACE
  • COMMONLY USED ABBREVIATIONS AND ACRONYMS
  • EXECUTIVE SUMMARY
  • SUMMARY OF OCCURRENCE AND HEALTH EFFECTS
  • 1.0. BACKGROUND
  • 1.1. PHYSICAL AND CHEMICAL PROPERTIES
  • 1.2. OCCURRENCE
  • 1.3. TOXICOKINETICS
  • 2.0. PROBLEM FORMULATION
  • 2.1. CONCEPTUAL MODEL
  • 2.2. OBJECTIVE
  • 2.3. METHODS
  • 3.0. OVERVIEW OF EVIDENCE IDENTIFICATION FOR SYNTHESIS AND DOSE-RESPONSE ANALYSIS
  • 3.1. LITERATURE SEARCH AND SCREENING RESULTS
  • 3.2. STUDY EVALUATION RESULTS
  • 4.0. EVIDENCE SYNTHESIS: OVERVIEW OF INCLUDED STUDIES
  • 4.1. THYROID EFFECTS
  • 4.2. REPRODUCTIVE EFFECTS
  • 4.3. OFFSPRING GROWTH AND EARLY DEVELOPMENT
  • 4.4. RENAL EFFECTS
  • 4.5. HEPATIC EFFECTS
  • 4.6. EFFECTS ON LIPIDS OR LIPOPROTEINS
  • 4.7. OTHER EFFECTS
  • 4.8. OTHER DATA
  • 5.0. EVIDENCE INTEGRATION AND HAZARD CHARACTERIZATION
  • 5.1. THYROID EFFECTS
  • 5.2. DEVELOPMENTAL EFFECTS
  • 5.3. REPRODUCTIVE EFFECTS
  • 5.4. RENAL EFFECTS
  • 5.5. HEPATIC EFFECTS
  • 5.6. EFFECTS ON LIPIDS OR LIPOPROTEINS
  • 5.7. IMMUNE EFFECTS
  • 5.8. CARDIOVASCULAR EFFECTS
  • 5.9. EVIDENCE INTEGRATION AND HAZARD CHARACTERIZATION SUMMARY
  • 6.0. DERIVATION OF VALUES
  • 6.1. DERIVATION OF ORAL REFERENCE DOSES
  • 6.2. DERIVATION OF INHALATION REFERENCE CONCENTRATIONS
  • 6.3. CANCER WEIGHT-OF-EVIDENCE DESCRIPTOR AND DERIVATION OF CANCER RISK VALUES
  • 6.4. SUSCEPTIBLE POPULATIONS AND LIFE STAGES
  • APPENDIX A. LITERATURE SEARCH STRATEGY
  • APPENDIX B. DETAILED PECO CRITERIA
  • APPENDIX C. STUDY EVALUATION METHODS
  • APPENDIX D. HAWC USER GUIDE AND FREQUENTLY ASKED QUESTIONS
  • APPENDIX E. ADDITIONAL DATA FIGURES
  • APPENDIX F. BENCHMARK DOSE MODELING RESULTS
  • APPENDIX G. QUALITY ASSURANCE
  • APPENDIX H. REFERENCES.

Ejemplares similares